Non-melanoma skin cancers in elderly patients

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 3, 2011, Pages 474-480

  Perrotta, Rosario Emanuele ^a   Giordano, Maria ^a   Malaguarnera, Mariano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Elderly patients; Immunosenescence; Immunosuppression; Skin cancer; Squamocellular carcinoma; T regulatory cells

Indexed keywords

AMILORIDE; AZATHIOPRINE; CD28 ANTIGEN; CYCLOSPORIN A; FAS ANTIGEN; FLUOROURACIL; FUROSEMIDE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LOOP DIURETIC AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; RESIQUIMOD; THIAZIDE DIURETIC AGENT; TIOGUANINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; B LYMPHOCYTE; CANCER RADIOTHERAPY; CAUTERIZATION; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONAL ANERGY; CRYOTHERAPY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; DRUG TOLERABILITY; GERIATRIC PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INNATE IMMUNITY; NATURAL KILLER CELL; NON MELANOMA SKIN CANCER; PHOTODYNAMIC THERAPY; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CANCER; SKIN SURGERY; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; AGING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; SKIN NEOPLASMS;

EID: 80655149160     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.04.011     Document Type: Review

References (80)

1. Chia KS, Seow A, Lee HP, Shanmugaratnam K. Cancer Incidence in Singapore, 1993-1997. Singapore Cancer Registry Report No.5. Singapore: Singapore Cancer Registry 2000.
2. Weinstock M.A. Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island follow-back study. J Invest Dermatol 1994, 102:6S-9S.
3. Reichrath J. Skin cancer prevention and UV-protection: how to avoid vitamin D-deficiency?. Br J Dermatol 2009, 161:54-60.
4. Green A., Beardmore G., Hart V., et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988, 19:1045-1052.
5. Takahashi H., Iizuka H., Nakashima M., et al. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. J Dermatol Sci 2001, 26:140-144.
6. Sonoda K., Kaku T., Kamura T., et al. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin Cancer Res 1998, 4:1517-1520.
7. Prall F., Nollau P., Neumaier M., et al. CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium and myeloid cells in a wide range of normal human tissues. J Histochem Cytochem 1995, 44:35-41.
8. Koseki S., Aoki T., Ansai S., Hozumi Y., Mitsuhashi Y., Kondo S. An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis. J Dermatol 1999, 26:416-422.
9. Malaguarnera M., Laurino A., Di Mauro S., Motta M., Di Fazio I., Maugeri D. The comorbidities of elderly oncologic patients. Arch Gerontol Geriatr 2000, 30:237-244.
10. Finkel T., Serrano M., Blasco M.A. The common biology of cancer and ageing. Nature 2007, 448:767-774.
11. Malaguarnera L., Ferlito L., Di Mauro S., Imbesi R.M., Scalia G., Malaguarnera M. Immunosenescence and cancer: a review. Arch Gerontol Geriatr 2001, 32:77-93.
12. Motta M., Ferlito L., Malaguarnera L., et al. Alterations of the lymphocytic set-up in elderly patients with cancer. Arch Gerontol Geriatr 2003, 36:7-14.
13. Malaguarnera L., Cristaldi E., Malaguarnera M. The role of immunity in elderly cancer. Oncol Hematol 2010, 74:40-60.
14. Malaguarnera L., Cristaldi E., Vinci M., Malaguarnera M. The role of exercise on the innate immunity of the elderly. Eur Rev Aging Phys Act 2008, 5:43-49.
15. Franceschi C., Valensis S., Fagnoni S., Barbi C., Bonafe M. Biomarkers of immunosenescence within an evolutionary perspective: the challenge of heterogenicity and the role of antigenic load. Exp Gerontol 1999, 34:911-921.
16. Hu A., Ehleiter D., Ben-Yeuda A. Effect of age on the expressed B cell repertoire: role of B cell subsets. Int Immunol 1993, 5:1035-1039.
17. Nicoletti C. Antibody protection in aging: influence of idiotypic repertoire and antibody binding activity to a bacterial antigen. Exp Mol Pathol 1995, 62:99-108.
18. Burns E.A., Goodwin J.S. Immunological changes of aging. Comprehensive Geriatric Oncology 1998, 213. Harwood Academic Publishers, The Netherlands. L. Balducci, G.H. Lyman, W.B. Ershler (Eds.).
19. Ortaldo J.R. Regulation of natural killer cells. Cancer Metast Rev 1987, 6:637-651.
20. Kutza J., Murasko D.M. Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples. Mech Ageing Dev 1996, 90:209-222.
21. Provinciali M., Di Stefano G., Stronati S., Fabris N. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients. Cytokine 1998, 10:132-139.
22. Borrego F., Alonso M.C., Galiani M.D., et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 1999, 34:253-265.
23. Linton P.J., Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004, 5:133-139.
24. Gruver A.L., Hudson L.L., Sempowski G.D. Immunosenescence of ageing. J Pathol 2007, 211:144-156.
25. Effros R.B. Long-term immunological memory against viruses. Mech Ageing Dev 2000, 121:161-171.
26. Ginaldi L., De Martinis M., D'Ostilio A., et al. The immune system in the elderly. I. Specific humoral immunity. Immunol Res 1999, 20:101-108.
27. Ginaldi L., De Martinis M., D'Ostilio A., et al. The immune system in the elderly. II. Specific cellular immunity. Immunol Res 1999, 20:109-115.
28. Van Aman S.E., Whisler R.L. Differential expression of p53 tumor suppressor protein and IL-2 in activated T cells from elderly humans. J Interferon Cytokine Res 1998, 18:315-320.
29. Urbaniak-Kujda D., Kapelko-Słowik K., Wołowiec D., et al. Increased percentage of CD8+CD28- suppressor lymphocytes in peripheral blood and skin infiltrates correlates with advanced disease in patients with cutaneous T-cell lymphomas. Postepy Hig Med Dosw 2009, 63:355-359. [Online].
30. Romedahl C.A., Donawho C., Fidler I.J., Kripke M.L. Effect of ultraviolet-B radiation on the in vivo growth of mucine melanoma cells. Cancer Res 1988, 48:4007-4010.
31. Kripke M.L. Effects of UV radiation on tumor immunity. J Natl Cancer Inst 1990, 82:1392-1396.
32. Kripke M.L. Immunologic mechanism in UV radiation carcinogenesis. Adv Cancer Res 1981, 34:69-106.
33. Shearer G.M. Th1/Th2 changes in aging. Mech Ageing Dev 1997, 94:1.
34. Rink L., Cakman I., Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998, 102:199.
35. Sakaguchi S., Takahashi T., Yamazaki S., et al. Immunologic self tolerance maintained by T-cell-mediated control of self reactive T cells: implications for autoimmunity and tumor immunity. Microb Infect 2001, 3:911-918.
36. Belkaid Y., Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6:353-360.
37. Toda A., Piccirillo C.A. Development and function of naturally occurring CD4+ CD25+ regulatory T cells. J Leukoc Biol 2006, 80:458-470.
38. Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-b induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
39. Peng Y., Laouar Y., Li M.O., Green E.A., Flavell R.A. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 2004, 101:4572-4577.
40. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
41. Cella M., Sullusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997, 9:10-16.
42. + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000, 30:1538-1543.
43. DiPaolo R.J., Brinster C., Davidson T.S., Andersson J., Glass D., Shevach E.M. Autoantigen-specific TGF_-induced Foxp3_ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 2007, 179:4685-4693.
44. Mahnke K., Qian Y., Knop J., Enk A.H. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003, 101:4862-4869.
45. Asgari M.M., Chren M.M., Warton E.M., Friedman G.D., White E. Association of use of nonsteroidal anti-inflammatory drugs and cutaneous squamous cell carcinoma. Arch Dermatol 2010, 146:388-395.
46. Ono M. Molecular links between tumor angiogenesis and inflammation; inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008, 99:1501-1506.
47. Fecker L.F., Stockfleth E., Nindl I., Ulrich C., Forschner T., Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007, 156:25-33.
48. Jensen A., Thomsen H.F., Engebjerg M.C., Olesen A.B., Sorensen H.T., Karagas M.R. Use of photosensitizing diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008, 99:1522-1528.
49. Moore D.E. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002, 25:345-372.
50. Frishman W.H., Brosnan B.D., Grossman M., Dasgupta D., Sun D.K. Adverse dermatologic effects of cardiovascular drug therapy: part II. Cardiol Rev 2002, 10:285-300.
51. Schwarze H.P., Albes B., Marguery M.C., Loche F., Bazex J. Evaluation of drug-induced photosensitivity by UVB photopatch testing. Contact Dermatitis 1998, 39:200.
52. Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull 1987, 34:3-5.
53. Queille S., Luron L., Spatz A., et al. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis 2007, 28:724-731.
54. London N., Farmery S., Will E., Davison A., Lodge J. Risk of neoplasia in renal transplant patients 1995, 714(346):403-406. [published erratum appears in Lancet 1995;346:714].
55. Hardie I.R., Strong R.W., Hartley L.C.J., Woodruff P.W.H., Clunie G.J.A. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980, 87:177-183.
56. Hiesse C., Kriaa F., Rieu P., et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 1995, 27:972-974.
57. McGregor J., Proby C. Skin cancer in transplant recipients. Lancet 1995, 346:964-965.
58. Andre N., Roquelaure B., Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses 2004, 63:647-652.
59. Yarosh D., Canning M., Teicher D., Brown D. After sun reversal of DNA damage: enhancing skin repair. Mutat Res 2005, 571:57-64.
60. Lennard L., Thomas S., Harrington C., Maddocks J. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985, 113:723-729.
61. Swann P., Waters T., Moulton D., et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996, 273:1109-1111.
62. Taylor A., Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol 1992, 72:115-119.
63. Rehman I., Quinn A.G., Takata M., Taylor A.E.M., Rees J.L. Low frequency of allelic loss in skin tumours from immunosuppressed individuals. Br J Cancer 1997, 76:757-759.
64. Knudson A. Genetic events in human carcinogenesis. Origins of Human Cancer 1991, 17-26. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. J. Brugge, T. Curran, E. Harlow, F. McCormick (Eds.).
65. Arlette J.P., Trotter M.J. Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment. Australas J Dermatol 2004, 45:1-11.
66. Palamara F., Meindl S., Holcmann M., Luhrs P., Stingl G., Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004, 173:3051-3061.
67. Urosevic M., Dummer R., Conrad C., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005, 97:1143-1153.
68. Amini S., Viera M.H., Valins W., Berman B. Nonsurgical innovations in the treatment on nonmelanoma skin cancer. J Clin Aesthet Dermatol 2010, 3:20-34.
69. Clark R.A., Huang S.J., Murphy G.F., et al. Human squamous cell carcinomas evade the immune response by down regulation of vascular E selectin and recruitment of regulatory T cells. J Exp Med 2008, 205:2221-2234.
70. Huang S.J., Hijen D., Murphy G.F., et al. Imiquimod enhances IFNγ production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol 2009, 129:2676-2685.
71. Sisto Alessi S., Sanches J.A., Roncalli de Oliveira W., Messina M.C., de Almeida Pimentel E.R., Neto C.F. Treatment of cutaneous tumors with topical 5% imiquimod cream. Clin Sci 2009, 64:961-966.
72. Beutner K.R., Geisse J.K., Helman D., Fox T.L., Ginkel A., Owens M.L. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999, 41:1002-1007.
73. Geisse J.K., Rich P., Pandya A., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002, 47:390-398.
74. Mackenzie-Wood A., Kossard S., de Launey J., Wilkinson B., Owens M.L. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001, 44:462-470.
75. Michelle S.Y.G. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol 2006, 47:186-188.
76. Ulrich C., Bichel J., Euvrard S., et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007, 157:25-31.
77. Jones T. Resiquimod 3M. Curr Opin Invest Drugs 2003, 4:214-218.
78. Szeimies R.M., Bichel J., Ortonne J.P., Stockfleth E., Lee J., Meng T.C. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008, 159:205-210.
79. Malaguarnera L., Ferlito L., Imbesi R.M., et al. Immunosenescence: a review. Arch Gerontol Geriatr 2001, 32:1-14.
80. Malaguarnera L., Cristaldi E., Lipari H., Malaguarnera M. Acquired immunity: immunosenescence and physical activity. Eur Rev Aging Phys Act 2008, 5:61-69.